Terns Pharmaceuticals, Inc. Material Event - Merger with Merck & Co., Inc.

This breakdown explains the latest news regarding Terns Pharmaceuticals in plain English to help you understand what this means for your investment.

1. What happened?

Merck & Co., Inc. has agreed to acquire Terns Pharmaceuticals. Merck will pay $53.00 per share in cash, valuing the company at approximately $3.8 billion. Once the deal closes, Terns will cease to be an independent, publicly traded company and will operate as a subsidiary of Merck.

2. Why is this happening?

Large pharmaceutical companies often acquire smaller firms to bolster their research pipelines. Terns specializes in treatments for cancer and metabolic diseases, most notably its lead drug, TERN-701. This deal provides Terns shareholders with a guaranteed cash payout and provides Terns’ experimental drugs with the significant funding and global distribution capabilities that only a company like Merck can offer.

3. What does this mean for you?

• For Stockholders: You are being "cashed out." The $53.00 offer represents a 42% premium over the stock’s closing price on March 23, 2026.
• For Employees: All outstanding stock options and restricted stock units will be converted into cash at the $53.00 per share price upon the closing of the deal.
• For Patients: This is generally viewed as a positive development. Merck’s resources may accelerate Terns’ ongoing clinical trials, potentially bringing new treatments to patients more quickly.

4. What happens next?

The merger is subject to approval by Terns’ shareholders and government regulators. The companies anticipate closing the deal by March 2027. In the meantime, Terns will continue its daily operations and clinical trials as usual.

5. Key takeaways for investors

• The "Spread": You may notice the stock trading slightly below $53.00. This small gap, known as the "merger spread," reflects the time value of money and the inherent risk that regulators could delay or block the transaction.
• Regulatory Hurdles: Because regulators are currently scrutinizing the pharmaceutical industry, there is a possibility of requests for additional information, which could push the closing date beyond March 2027.
• Your Strategy: Most shareholders simply hold their shares until the deal is finalized. Once the merger closes, the cash proceeds will be deposited automatically into your brokerage account. There is no action required on your part to receive these funds.

Disclaimer: I am an AI, not a financial advisor. This summary is for informational purposes only and does not constitute financial advice. Investment decisions involve risk; please consult with a qualified professional or conduct your own thorough research before taking action.